Thor Medical ASA
OSE:TRMED
Thor Medical ASA
EPS (Diluted)
Thor Medical ASA
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
T
|
Thor Medical ASA
OSE:TRMED
|
EPS (Diluted)
kr0
|
CAGR 3-Years
66%
|
CAGR 5-Years
53%
|
CAGR 10-Years
26%
|
|
|
Hofseth Biocare ASA
OSE:HBC
|
EPS (Diluted)
kr0
|
CAGR 3-Years
5%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
6%
|
|
|
B
|
Bergenbio ASA
OSE:BGBIO
|
EPS (Diluted)
-kr3
|
CAGR 3-Years
54%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
L
|
Lytix Biopharma AS
OSE:LYTIX
|
EPS (Diluted)
-kr1
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
|
Arcticzymes Technologies ASA
OSE:AZT
|
EPS (Diluted)
kr0
|
CAGR 3-Years
-45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
N
|
Nykode Therapeutics ASA
OSE:NYKD
|
EPS (Diluted)
$0
|
CAGR 3-Years
-59%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
Thor Medical ASA
Glance View
Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The company is headquartered in Oslo, Oslo and currently employs 16 full-time employees. The company went IPO on 2014-07-07. The firm is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The firm is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
See Also
What is Thor Medical ASA's EPS (Diluted)?
EPS (Diluted)
-0.2
NOK
Based on the financial report for Jun 30, 2024, Thor Medical ASA's EPS (Diluted) amounts to -0.2 NOK.
What is Thor Medical ASA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
26%
Over the last year, the EPS (Diluted) growth was 87%. The average annual EPS (Diluted) growth rates for Thor Medical ASA have been 66% over the past three years , 53% over the past five years , and 26% over the past ten years .
You don't have any saved screeners yet